




RealRate

PHARMACEUTICAL 2021

Korro Bio Inc
Rank 129 of 394

FREQUENCY
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Korro Bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Korro Bio Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Korro Bio Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 325%, being 68% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	225,064
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,634
Liabilities, Non-Current	30,597
Other Assets	32,371
Other Compr. Net Income	-27
Other Expenses	35
Other Liabilities	15,000
Other Net Income	1,074
Other Revenues	36,984
Property and Equipment	7,287
Research and Development	37,415
Selling, General and Administrative Expense	27,119

Output Variable	Value in 1000 USD
Assets	264,722
Liabilities	72,231
Expenses	64,569
Revenues	36,984
Stockholders Equity	192,491
Net Income	-26,511
Comprehensive Net Income	-26,524
BaseVar	219,804
ECR before LimitedLiability	233%
Economic Capital Ratio	325%